While Rescheduling Unifies Some Federal Tax Treatment, California Cannabis and Hemp Keep Diverging Along the THC Line

What the divide means for entity choice, ownership, exits, and the post-rescheduling tax math

By Shay Aaron Gilmore | The Law Office of Shay Aaron Gilmore | June 2026

Cannabis and hemp are the same plant under two bodies of law, and for a California operator the gap between them decides almost everything that matters: how the business is taxed, who must be disclosed as an owner, what happens to its permit on a sale, and which regulators can shut it down. The dividing line has always been THC content, but it is worth being precise about which line and where it is measured.

The federal line separating lawful hemp from Schedule I marijuana has run on delta-9 THC since the 2014 Farm Bill set it at 0.3 percent by dry weight and the 2018 Farm Bill carried that figure forward; California measures its crop the same way, field-testing on a delta-9 (post-decarboxylation) basis before harvest (CDFA, Industrial Hemp FAQ). In 2021 the state added a second, stricter line on the product side: since AB 45, a hemp product sold here has had to test at no more than 0.3 percent total THC — delta-8, delta-9, delta-10, and THCA summed — in its final form, with THC isolate and synthetic cannabinoids barred outright, a standard CDPH calls “stricter than federal law” (CDPH, Intoxicating Cannabinoids ISOR, DPH-24-005B; AB 45 (2021)). So the plant can pass the delta-9 crop test in the field yet yield finished goods that fail California’s total-THC product test — goods that today can and do move out of state into markets that permit them, a federally protected pathway the coming November 2026 redefinition is poised to close.

In 2026 the federal line moves toward where California’s product line already runs. Effective November 12, 2026, the FY2026 agriculture appropriations act redefines hemp by total THC — folding in THCA and the converted cannabinoids the delta-9-only test has let through — and caps a product at no more than 0.4 milligrams of total THC per container (P.L. 119-37). Unlike California’s product test, this change rewrites the federal definition of hemp itself, so it reaches the plant and the crop test, not only the finished product. People tend to describe the line in terms of intoxication (and the “intoxication” term is heavily debated), but legally it is a numerical threshold: product under the limit keeps its lighter agricultural treatment, and product over the limit loses hemp’s federal safe harbor and becomes lawful only as cannabis licensed by the DCC.

But now the cannabis system no longer carries one federal tax answer. The April 2026 federal order eased Internal Revenue Code § 280E for only two narrow categories moved to Schedule III: marijuana held under a state medical license, and FDA-approved marijuana drug products. Everything else — adult-use, unlicensed, and bulk marijuana — stays in Schedule I under the full § 280E burden. This blog post assumes this split holds: the June 29, 2026 hearing on broader rescheduling is unresolved as of this writing, and full rescheduling of all marijuana — medical and adult-use alike — would dissolve the medical-versus-adult-use distinction at the center of the current tax picture.

What follows compares the two regimes — cannabis and hemp — at each decision point a California operator actually faces: entity and tax, ownership disclosure, exits, and ongoing compliance. I will cover the cannabis side of this in the California Lawyers Association’s June 11, 2026 webinar, California Cannabis Industry: An Overview of Regulatory and Tax Compliance, which I will present with tax specialist Ani Galyan; here in this blog post I take the analysis across the cannabis–hemp divide.

Entity Choice: The Same Forms, Two Different Tax Worlds

Entity selection starts from the same freedom in both cannabis and hemp regimes: the Franchise Tax Board confirms a cannabis licensee “can choose any form of valid business structure,” and hemp carries no entity restriction either (California Franchise Tax Board). What differs is the tax pressure behind the choice. For a hemp founder, the entity question is the ordinary one any business asks. For a cannabis founder, the same menu has to be read through a federal tax penalty that can make the textbook-correct entity the wrong one.

Why § 280E changes the cannabis answer

The tax gap between the two regimes traces to one federal statute. Internal Revenue Code § 280E disallows ordinary business deductions — but not cost of goods sold — for any trade or business “trafficking in controlled substances (within the meaning of schedule I and II of the Controlled Substances Act)” (26 U.S.C. § 280E). A cannabis business is therefore taxed federally on something close to gross profit, not net, pushing its effective rate well above nominal; compliant hemp, never a controlled substance, deducts all of it.

But that fork is no longer static on the cannabis side. Because § 280E reaches only Schedule I and II substances, the Department of Justice’s April 2026 final order — moving marijuana held under a state medical license (or in an FDA-approved drug product) to Schedule III, while leaving unlicensed and adult-use marijuana in Schedule I — changes who carries the penalty: “to the extent marijuana is moved from Schedule I to Schedule III, marijuana businesses can deduct business expenses” (CRS, LSB11424). Treasury agreed the same day that the relief reaches a mixed business only for its relieved activities and only prospectively, for the full taxable year that includes the effective date (U.S. Department of the Treasury). So whether § 280E burdens a cannabis operator now turns first on schedule and then on structure — rescheduling does not erase the cannabis–hemp tax gap so much as split the cannabis side in two.

The same three entity forms, weighed in each world

Three forms carry almost every operating business in this space — the LLC, the C-corporation, and the Subchapter S corporation — and this is where the entity decision is actually made. Read in the ordinary way, an LLC is the default for most closely held ventures, a C-corp is the vehicle for outside equity investment and institutional capital, and an S-corp is a pass-through with payroll-tax advantages for a narrow band of qualifying owners. That ordinary ranking is exactly what hemp follows. What § 280E does, on the cannabis side, is reorder it.

Start with the LLC. For a hemp business it is the unremarkable default; for a cannabis business its pass-through treatment can be unfavorable. Because most deductions are disallowed federally, the owners owe personal federal tax on profit figures inflated by § 280E, so the tax bill can outrun the cash actually distributed to pay it — pass-through transparency, normally a feature, becomes the mechanism that pushes a phantom-income problem onto individual returns.

The C-corporation is, counterintuitively, often the defensive default on the cannabis side for the same reason it is merely one option among several on the hemp side. It absorbs the § 280E hit at the entity level rather than passing inflated income through to individuals, accommodates the multiple share classes outside equity investment requires, and isolates investors from the operating company’s tax posture. The double taxation that usually counts against a C-corp matters less here, because the first layer of tax is unavoidable anyway, and the structure at least keeps the § 280E hit from flowing onto the owners personally.

Subchapter S is usually impractical for cannabis, and for structural reasons rather than tax ones: its shareholder cap, single-class-of-stock rule, and bar on most entity and nonresident-alien shareholders collide with how cannabis capital actually comes in. For a hemp business with a small, eligible ownership group it can still be the sensible pass-through choice it is anywhere else.

The same pattern runs through all three: the form that looks ordinary for a hemp business looks defensive for a cannabis one. The menu is identical; what changes is the tax problem each form is being asked to solve. A hemp company chooses its entity on the same grounds as any other agricultural or consumer-products company, with none of these distortions in play.

The table below isolates the tax variable that can drive entity selection — whether § 280E applies. Outside § 280E (all hemp today, plus cannabis income moved to Schedule III by the April 2026 order), a business chooses its entity on ordinary grounds. Inside § 280E, it chooses defensively, because the penalty rewrites what each form costs its owners. The November 12, 2026 redefinition is what pushes much of the intoxicating-hemp market from the left side of that line to the right.

Entity form	Outside § 280E (all federally legal hemp; medical-licensed cannabis after April 2026 federal rescheduling)	Inside § 280E (adult-use cannabis after April 2026; intoxicating hemp after November 2026 redefinition)
LLC	Ordinary default — pass-through profit reaches owners untaxed at the entity level, as in any business	Unfavorable — § 280E inflates taxable income above the cash to pay it, and the pass-through sends that phantom income onto owners’ returns
C-corporation	One option among several — no § 280E penalty to contain, so it competes on ordinary grounds with the pass-throughs	Defensive default — absorbs the § 280E hit at the entity level, so inflated income never reaches owners personally
Subchapter S	Pass-through, like the LLC — profit reaches owners untaxed at the entity level	Unfavorable, like the LLC — as a pass-through it cannot absorb the § 280E hit, so the inflated income lands on owners’ returns

The fork inside hemp: which hemp for your operation?

Before deciding entity choice, a hemp founder has to answer a prior question, because “hemp” is no longer one regulatory thing. It is splitting into two branches that are moving in opposite directions relative to cannabis, and the entity, banking, and tax decisions that fit one branch are wrong for the other. Because the branching runs inside the hemp category rather than between hemp and cannabis, it is easy to miss.

• Non-intoxicating industrial hemp — fiber, grain, seed, and true CBD/CBN isolate — is moving further away from cannabis in terms of regulatory oversight. As regulators pull intoxicating products out of the hemp lane and into the DCC’s regulated supply chain, what is left is a more straightforwardly agricultural category: a crop and a set of non-intoxicating ingredients with no § 280E exposure, no DEA overlay, ordinary banking, and a lighter CDFA-registration and CDPH framework. The 2025 California and federal enactments mostly clarify this branch by pulling the harder cases out, so for a business that genuinely sits here, industrial hemp is becoming more distinct from cannabis, not less, and ordinary entity planning is the right approach.

• Intoxicating hemp — anything trading on a THC or THC-class cannabinoid effect — is being pulled into the regulated cannabis supply chain, and into its harsh § 280E tax environment. The federal redefinition by total THC — the FY2026 agriculture appropriations act (P.L. 119-37) now measures combined THC rather than delta-9 alone, effective November 12, 2026 — and California’s AB 8 (banning inhalable hemp-THC products now and routing cannabinoid extraction under DCC licensure by January 1, 2028) mean that by those dates this branch does not merely resemble cannabis; for structuring purposes it largely is cannabis — same licensing, same owner/FIH disclosure, same non-transferable permits, same multi-agency compliance load. And on tax it lands on the wrong side of the rescheduling split, because the relieved Schedule III tier reaches only products held under a state medicinal (M) license. A former-hemp operator could restructure into that channel; without that deliberate move the reclassified product defaults into adult-use Schedule I and carries the full § 280E penalty.

A further consequence hits California producers harder than most. Today, AB 45 lets California manufacturers make certain hemp products that cannot be sold in-state — inhalables most clearly — “for the sole purpose of sale out of state” (AB 45 (2021)), and Section 10114 of the 2018 Farm Bill bars any state from blocking interstate transport of federally compliant hemp — making California a lawful production base for goods legal where they are ultimately sold. The November 12, 2026 federal redefinition severs that chain: because Section 10114’s protection runs only to hemp meeting the federal definition, once that definition narrows to total THC with a 0.4-milligram-per-container cap and excludes converted cannabinoids, most current intoxicating-hemp formulations cease to be federally protected hemp. That export supply chain does not move into the DCC system; for products that cannot be reformulated under the new cap, it largely disappears, subject to any congressional change still in play and the FDA’s not-yet-issued list of covered cannabinoids (CRS, LSB11424). An intoxicating hemp operator who assumes California can keep manufacturing for those out-of-state markets is relying on an option that ends in November 2026.

So an initial structuring question for a hemp founder is no longer just “cannabis or hemp?” but also “which kind of hemp?” A company that treats itself as a single “hemp business” while selling across both branches is sitting on top of that split, and its intoxicating-hemp line should be structured for the cannabis regime it is moving into rather than the agricultural one it is leaving.

Crossing Into the DCC: What Changes About Ownership and the Exit When an Operator Leaves CDFA or CDPH for the DCC

Ownership disclosure and exit both turn on the same fact: which agency licenses the business. Under CDFA or CDPH, both questions stay manageable. Once an operator is licensed by the DCC, both become far more serious. For intoxicating-hemp operators this is no longer hypothetical — the November 12, 2026 federal redefinition and AB 8’s routing of cannabinoid extraction into DCC licensure by January 1, 2028 are moving a whole class of CDFA- and CDPH-permitted businesses into the cannabis regime.

Who counts as part of the business widens sharply at the DCC line

Hemp asks a narrow question. Cultivation isn’t DCC-licensed; growers register with CDFA through the county commissioner, which asks only who the “key participants” are — the sole proprietor, partners, or those with executive managerial control — with FBI vetting and changes reported within 15 days (3 CCR §§ 4901, 4902). The DCC asks a far broader one, reaching well beyond the cap table, as I have written before (The Law Office of Shay Aaron Gilmore). An “owner” under § 15003 is anyone with a 20-percent-or-more aggregate interest — reaching indirect holdings, so stacked structures don’t hide it — or anyone who manages, directs, or controls the business regardless of equity (Cal. Code Regs. tit. 4, § 15003). Below that, the Financial Interest Holder category captures sub-20-percent investors, lenders, and profit-share partners, subject to exclusions (Cal. Code Regs. tit. 4, § 15004). An operator migrating into the DCC must therefore disclose and vet people — passive investors, lenders, control persons — who never appeared in a CDFA key-participant filing.

Non-transferability is a routine filing at CDFA or CDPH and a deal-defining constraint at the DCC

None of these permits can be sold or assigned — not the cannabis license (Cal. Code Regs. tit. 4, § 15023), not the CDFA cultivation registration (3 CCR § 4901(b)(1)), not the CDPH IHEO product authorization (17 CCR § 23210(e)). The rule reads the same in each, but it carries very different consequences depending on which regime an operator is in.

For a hemp operator the rule is technically strict but easy to live with. Any change in ownership voids the existing permit and requires a fresh application — there is no amendment process and no allowance for a partial change — but a CDFA or CDPH re-registration is a filing with modest fees that does not stop the business from operating. In practice the seller’s permit lapses, the buyer applies in its own name, and the deal is built around that step.

At the DCC, the same prohibition operates very differently. Because the license is personal to the licensed entity and its vetted owners, a sale cannot be a sale of the license; it has to be a transfer of the entity, and any change in who owns or controls that entity is itself a regulated event the DCC must approve. California cannabis M&A is therefore overwhelmingly an equity deal structured as a change of ownership of the licensed entity rather than a sale of the license. The buyer takes the company whole, including its liabilities and compliance history, so diligence is demanding and a clean asset carve-out is rarely available. A change of control can also leave the company in limbo while the incoming owners are vetted.

For an operator migrating into the DCC, the practical point is straightforward: the same non-transferability rule that is a routine re-filing under CDFA or CDPH becomes, once the product is regulated by the DCC, a vetted and approval-gated transaction that can halt the business while it is pending. The regulation does not change at that line, but what it means for a sale of the business does change materially.

Rescheduling Solved One Problem But Created Several Others — None of Which Hemp Has to Touch

The April 2026 rescheduling order loosened the federal tax treatment of medical marijuana — but it also added a new layer of registration, structuring, and compliance work to capture that benefit. The relief is genuine, but so is the added complexity. A non-intoxicating hemp business, federally lawful as a single entity, does not have to deal with any of this.

The relief, and the strings attached

The order rescheduling state-licensed medical marijuana to Schedule III gave California medicinal licensees an expedited DEA-registration window, and the benefit attaches to an entity that holds the right kind of license, not to a plant or a brand (DCC Finding of Emergency, DCC-2026-03-E). The relief is limited in two ways worth keeping in mind. It is prospective, reaching the full 2026 tax year but not closed years (Treasury), pending further IRS guidance, and the relief is not totally secure, because a proposal in the 119th Congress would deny marijuana deductions “regardless of schedule” by statute (CRS, LSB11424). The relief may be worth claiming, but it is not a foundation to build a structure on if that structure only works while the current federal posture holds.

Three complications the relief creates

The relief does not arrive automatically, and claiming it brings three problems that a hemp business never has to confront.

The first is a deadline. The DEA grants expedited treatment — a six-month review, with the right to keep operating under an existing state license while the application is pending — only to operators who file within 60 days of Federal Register publication, which is a June 27, 2026 deadline for the April 28 publication (U.S. Drug Enforcement Administration). Filing late does not bar registration, but it gives up the ability to operate during review, which is a reason to move now. And because the order reached only medical marijuana, whether Schedule III extends to adult-use marijuana is the subject of a DEA hearing that begins June 29, 2026 (California NORML).

The second is a structural one. Because most California retailers sell both adult-use and medical product, the DCC’s emergency package DCC-2026-03-E lets a retailer hold separate A (adult-use) and M (medicinal) licenses at one premises through two entities that share owners but remain jointly and severally liable for each other’s violations (DCC-2026-03-E Proposed Text). The separation on paper does not separate the underlying liability, so the governance and intercompany terms have to be set up carefully at formation and treated as provisional.

The third is that key rules are still unwritten. Conforming regulations do not yet exist for track-and-trace across the two co-located entities, for physician certification of a Schedule III product, or for a federal owner-disclosure standard that is broader than California’s 20-percent threshold. These are gaps to plan around rather than wait on. A non-intoxicating hemp operator has none of these obligations to track.

Staying Compliant: Two Lanes, and No Neutral Ground Between Them

A point founders often miss is that there is no neutral middle. Product is either DCC-compliant cannabis or CDFA/CDPH-compliant hemp; anything that is neither falls out of both legal markets into the illicit one, where it is contraband subject to seizure, destruction, and, since AB 8, criminal exposure. The lanes also run on different clocks. A cannabis operator lives under the DCC, CDFA, CDPH, and its local authority on a continuous cadence — Metrc reporting, a 14-day window for ownership and control changes, and a rulemaking docket that never closes (DCC regulations; CA AB 141). A hemp grower answers mainly to the county agricultural commissioner, with CDPH over products — no Metrc, but three negligent violations in five years bar a grower from registration for five years (Food and Agricultural Code § 81012).

Often a routine corporate event is what pushes a business out of its lane. In cannabis, because §§ 15003–15004 reach 20-percent holders, control persons, and many investors and lenders, an ordinary financing triggers DCC disclosure on the 14-day clock — a sound deal still produces a violation if no one files in time (§ 15003; § 15004). Hemp’s version is sharper: an ownership change requires an entirely new registration application, and a late filing renders the crop condemnable (3 CCR § 4901(b)). Local authorization is a second license, too — under Proposition 64 a city or county may ban cannabis, so losing either state or local approval shuts the business down.

Hemp does carry the lighter regulatory load, but only the non-intoxicating cultivation business that stays clear of the DCC, and that space is narrowing. In 2028, AB 8 moves hemp cannabinoid extraction into MAUCRSA and brings the full Metrc system with it. And the two regulatory agencies are already aligning their testing rules: CDPH’s pending DPH-24-005 rulemaking, which makes its AB 45 hemp-food limits permanent, expressly adopts the DCC’s limit-of-detection definition and testing methods “to clarify that the Department is aligned with DCC’s regulations” (CDPH DPH-24-005) — a sign of how deliberately the two rulebooks are converging. The practical response is straightforward: keep clean protocols on file, stay adaptable, and track the rulemaking, because AB 8 now lets the state seize and destroy noncompliant product and attaches new misdemeanor liability to it (AB 8 (Chapter 248, Statutes of 2025)). Handled in advance, these are inexpensive to avoid; handled after the fact, they are expensive to fix. I cover the formation and registration mechanics on my hemp business formation and California hemp registration pages, and the ongoing work on my regulatory-compliance practice page.

Operators Across Four Dates, Federal and State, Over 18 Months

The pieces are easier to compare side by side than in sequence. The first column names the operator’s principal California regulator — CDFA for hemp cultivation as a crop, CDPH for hemp products and extraction, DCC for cannabis — and the remaining cells show the federal tax posture (the CSA schedule, and so whether § 280E applies) across the four dates over the next 18 months that reorder this field. It is a planning aid, not advice on a specific business, and this information remains subject to the FDA’s pending cannabinoid list and any congressional change before November 2026.

Operator (CA regulator)	Pre–Apr 2026	Post–Apr 2026 rescheduling	Post–Nov 2026 hemp redefined	Post–Jan 2028 THC Hemp to DCC
Intoxicating hemp products manufacturer (CDPH); intoxicating hemp cultivator (CDFA)	Federal Hemp — no § 280E	Federal Hemp — no § 280E	Products moved back under CSA Schedule I — full § 280E; cultivars fail the total-THC plant test → marijuana, Schedule I	A-license: Schedule I — full § 280E (CDPH → DCC); M-license: Schedule III — § 280E lifts (CDFA → DCC)
Non-intoxicating hemp products manufacturer (CDPH) or cultivator (CDFA)	Federal Hemp — no § 280E	Federal Hemp — no § 280E	Federal Hemp — no § 280E	Federal Hemp — no § 280E
Dual (A + M) cannabis licensee (DCC)	Federal Schedule I — full § 280E	Federal Split: M line → Schedule III (§ 280E lifts), A line stays Schedule I (full § 280E) — apportion	Federal Split — apportion between medical and non-medical cannabis	Federal Split — apportion between medical and non-medical cannabis

What stands out is which rows change and when. The intoxicating-hemp products manufacturer starts outside § 280E; once the November 2026 redefinition strips its federal hemp status it defaults into Schedule I, and where it lands after AB 8 routes it into the DCC turns on the license it takes — an adult-use license keeps it under the full penalty, while a deliberate move into a medicinal (M) channel reaches the Schedule III lane the April 2026 order opened. The intoxicating-hemp cultivator is hit a step earlier, at the plant itself: a high-THCA cultivar that cleared the old delta-9 field test can exceed the new total-THC measure, so the redefinition can push the crop into marijuana before any product is made. The non-intoxicating counterpart does not move — a CDPH-regulated isolate maker or CDFA-registered cultivator of compliant plants never faces § 280E at all.

Looking Ahead

California’s cannabis system is far more forgiving of companies built and documented like real businesses than of those put together as they go. Entity choice, ownership disclosure, the documents that govern control, and how a future sale is preserved are corporate-law decisions, and in cannabis each is also a question of survival for the business, which has to stay compliant inside a multi-agency regime that does not pause. Hemp runs alongside all of this as a separate regime whose regulatory line is moving in the opposite direction — while rescheduling is loosening the posture on licensed medical marijuana, P.L. 119-37 and AB 8 are tightening the rules on intoxicating hemp — narrowing what qualifies as hemp and routing cannabinoid extraction into DCC licensure by 2028.

My law practice is built for decision-making in this space — entity formation, ownership and financial-interest structuring, governance, the equity deals that stand in for M&A when a license can’t be sold, and the compliance work that keeps a license alive. Whether forming a company, navigating a compliance question, or weighing a sale, these are decisions worth getting right before they are forced by events.

This post is for general informational purposes and is not legal advice. The landscape described here is current as of early June 2026 and is changing rapidly: the expedited DEA registration window (60 days from the April 28, 2026 Federal Register publication, with a June 27, 2026 deadline), the June 29, 2026 administrative hearing on broader rescheduling, and the DCC-2026-03-E rulemaking were all live and unresolved as of this writing on the cannabis side. On the hemp side, P.L. 119-37’s total-THC redefinition takes effect November 12, 2026, and AB 8’s transition of hemp cannabinoid extraction into DCC licensure takes effect January 1, 2028, with implementing details still to come from the FDA, CDPH, and DCC.